Abbott Laboratories (ABT) 55.29 0.00

Abbott Laboratories
(ABT) 55.29 0.00

Last Trade:	55.11	Day Range:	55.11 - 55.11
Trade Time:	04:02PM	52wk Range:	45.28 - 56.84
Prev. Close:	55.11	Market Cap:	85.85B
Open:	0.00	Div Yield:	3.41
Volume:	0	PE:	180
EPS:	3.01

The Latest On ABT

Study Shows Abbott's Tacrolimus Assay Demonstrates Consistent Organ Transplant Drug Monitoring 2/13/12 9:01am

DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases 1/30/12 6:41am

JP Morgan Comments on 4Q Results for Abbott Laboratories 1/25/12 3:00pm

Earnings Roundup 1/25/12 9:25am

UPDATE: Abbott Laboratories Reports 12% Rise In Q4 Profit 1/25/12 9:07am

US Stock Futures Mixed; All Eyes On FOMC 1/25/12 6:36am

Earnings Scheduled For January 25 1/25/12 1:44am

Stocks To Watch For January 25 1/25/12 1:21am

Best Specialty Pharma Stocks Picked by UBS 1/20/12 6:27pm

The Mitt Romney ETF Portfolio 1/19/12 1:24pm

Benzinga's M&A Chatter for Wednesday January 18, 2012 1/18/12 6:53pm

Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories 1/18/12 8:33am

Study Shows Abbott's Tacrolimus Assay Demonstrates Consistent Organ Transplant Drug Monitoring 2/13/12

DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases 1/30/12

JP Morgan Comments on 4Q Results for Abbott Laboratories 1/25/12

Earnings Roundup 1/25/12

UPDATE: Abbott Laboratories Reports 12% Rise In Q4 Profit 1/25/12

US Stock Futures Mixed; All Eyes On FOMC 1/25/12

Earnings Scheduled For January 25 1/25/12

Stocks To Watch For January 25 1/25/12

Best Specialty Pharma Stocks Picked by UBS 1/20/12

The Mitt Romney ETF Portfolio 1/19/12

Benzinga's M&A Chatter for Wednesday January 18, 2012 1/18/12

Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories 1/18/12

Stocks To Watch For January 25 1/25/12

Best Specialty Pharma Stocks Picked by UBS 1/20/12

The Mitt Romney ETF Portfolio 1/19/12

Benzinga's M&A Chatter for Wednesday January 18, 2012 1/18/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

8 High-Yielding Stocks That Are Showing Strong Momentum 1/4/12

ETF Showdown: Fun With Pharma 12/30/11

2011 Winners That Can Keep Their Mojo In 2012 12/30/11

These Stocks May Be Better Than Their Dow Equivalents 12/1/11

Mad Money Lightning Round: Cramer Likes Waste Management 11/22/11

Medtronic Earnings Preview: Analysts Expect Flat EPS, Rising Revenue 11/17/11

Checking In: Another Income Play 11/8/11

JP Morgan Comments on 4Q Results for Abbott Laboratories 1/25/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

End-of-Day Market Summary for December 27 2011 12/27/11

JP Morgan Reiterates Neural, $55 PT on Abbott Laboratories 12/27/11

End-of-Day Market Summary for November 18, 2011 11/18/11

Morgan Stanley Maintains Overweight Rating on Abbott Laboratories 11/14/11

JP Morgan Maintains Neutral Rating and $55 PT on Abbott Laboratories 11/7/11

Morgan Stanley Overweight on Abbott Laboratories 11/7/11

Morgan Stanley Overweight on Abbott Laboratories 11/4/11

UPDATE: Deutsche Bank Raising Price Target on Abbott Laboratories 10/27/11

UBS Price Target Changes for 10/24/2011 10/24/11

First Global Reiterates LT Outperform on Abbott 10/24/11

Trade ABT
NOW!

Partner Headlines

Another Reason to Worry About Profits: Uncle Sam is Propping Them Up With Tax Breaks 2/13/12

YCHARTS DIVIDEND DAILY: Some "Non-Royalty" Dividends Beat the Aristocrats 2/13/12

Gilead, Vertex and the Mystery of Missing Hep C Patients 2/13/12

How Piramal Almost Put Berkshire Hathaway out of Business 2/13/12

Betting On Biotech 2/10/12

Abbott Labs Offers Long, Solid Dividend History 2/10/12

The 10 Must-Know Market Forces for 2012 2/10/12

Johnson & Johnson (JNJ) - A Reliable Dividend Growth Stock 2/10/12

2 of the Safest Stock Bets Around 2/10/12

Healthy Health Care ETF? 2/9/12

Ten Big Pharma Stocks' Juicy Dividend Payouts, With Cash-on-Hand as Cushion 2/8/12

The Spin Zone 2/8/12

Press Releases

Study Shows Abbott's Tacrolimus Assay Demonstrates Consistent Organ Transplant Drug Monitoring 2/13/12 Newswire Story

Abbott Creates New Similac SimplySmart™ Baby Bottle with Innovative Features 2/8/12 Newswire Story

Big VC Biotech Spending on the Rise for 2012 2/8/12 Business Wire Story

Leading Analyst Firm Positions Absolute Software as a Visionary in Magic Quadrant 2/6/12 Newswire Story

RBCC Negotiates Funding Terms With n3D 2/6/12 Business Wire Story

Abbott to Present at Leerink Swann 2012 Global Healthcare Conference 2/1/12 Newswire Story

Absolute Software to Present at the 2012 Stifel Nicolaus Technology and Telecom Conference 2/1/12 Newswire Story

DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases 1/30/12 Newswire Story

RBCC Explores New Cures for Cancer, Brain Injuries & Headaches 1/30/12 Business Wire Story

Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011 1/25/12 Newswire Story

RBCC Vets Investment Banks for Capital Raise 1/23/12 Business Wire Story

Fitch Affirms Chicago, IL Sales Tax Bonds 'AA-'; Outlook Stable 1/20/12 Business Wire Story

Get the latest ABT stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Abbott Laboratories stock price.

Abbott Laboratories by YCharts

Abbott Laboratories (ABT) 55.29 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On ABT

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social